By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs - 2What's going around right now? COVID, flu, stomach bug on the rise
- 3Physicists and philosophers have long struggled to understand the nature of time: Here's why
- 4Manual for Picking the Ideal Wine Matching
- 5Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- French rapper Gims placed under investigation for 'aggravated money laundering'
- Key Business Regulations to Consider While Arranging Your Independent venture
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
